Last reviewed · How we verify
Immune thrombocytopenia
Approved treatments
- Efgartigimod · M. Peter Marinkovich
Efgartigimod alfa binds to FcRn, reducing circulating IgG, while hyaluronidase increases subcutaneous permeability. - Tavalisse · Rigel Pharms
Tavalisse works by blocking the activity of the FLT3 enzyme, which is involved in the production of platelets. - Vyvgart · Argenx Bv
Vyvgart works by binding to the p51 subunit of the FcRn receptor, preventing it from recycling antibodies back into the bloodstream.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Immune thrombocytopenia patent landscape — cliff calendar, originator estates, attackable patents
- Immune thrombocytopenia treatment landscape brief
- Immune thrombocytopenia treatment updates RSS
Frequently asked questions about Immune thrombocytopenia
What drugs treat Immune thrombocytopenia?
Tracked treatments include Efgartigimod, Tavalisse, Vyvgart.
What is the treatment for Immune thrombocytopenia?
Standard treatment for Immune thrombocytopenia includes Efgartigimod, Tavalisse, Vyvgart. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Immune thrombocytopenia patent cliff · Immune thrombocytopenia CI report
- Treatment: Efgartigimod · M. Peter Marinkovich
- Treatment: Tavalisse · Rigel Pharms
- Treatment: Vyvgart · Argenx Bv
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing